Pyxis Oncology Reports Q2 2026 Results, Extends Cash Runway into Q2 2027
PYXS has more than doubled off its 52-week low of $1.
Summary
Pyxis Oncology reported Q2 2026 financial results, extended its cash runway into Q2 2027, and provided updated clinical timelines for MICVO.
Key Events · Earnings and Guidance · PYXS
-
Q2 2026 Financial Results
Net loss of $25.3 million, or $0.40 per share, compared to $18.4 million, or $0.30 per share, in Q2 2025. R&D expenses were $16.1 million and G&A expenses were $9.9 million.
-
Cash Runway Extended
Cash and investments of $34.5 million as of June 30, 2026, plus $50 million upfront from the private placement, extends runway into Q2 2027.
-
Clinical Milestones
Updated monotherapy data from the MICVO Phase 1 study in 2L+ R/M HNSCC expected in Fall 2026; updated combination data with pembrolizumab expected in Q4 2026.
-
Share Count
Outstanding shares of 83,408,050 as of August 12, 2026.
Analysis · PYXS · Life Sciences
Pyxis Oncology reported a wider Q2 net loss of $25.3 million, but the key takeaway is the extended cash runway into the second quarter of 2027 following the $50 million upfront private placement. The company also provided updated clinical timelines for its lead asset MICVO, with monotherapy data expected in Fall 2026 and combination data in Q4 2026. These milestones are critical for a clinical-stage company with a going concern warning, as they represent the next potential value inflection points.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 29.9% of the 1661 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PYXS was trading at $3.21 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $201.5M. The 52-week trading range was $1.00 to $5.55. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.